FlowCAT offers flexible fixed-bed hydrogenation

Published: 22-Mar-2010
Manufacturing

Bench-top reactor produces results from millilitres of product

HEL, an international group of companies supplying process tools for the pharmaceutical industry, has introduced the FlowCAT continuous flow bench-top reactor, which is said to be a flexible and cost-effective choice in lab-scale fixed-bed hydrogenation.

HEL, headquartered in Borehamwood, Hertfordshire, UK, has developed a system that delivers high-pressure flow chemistry, with the flexibility to tune hydrogenation conditions to suit the chemistry.

The system design allows for rapid screening of process conditions, which is useful in the early stage generation of API intermediates, where the behaviour and chemistry of the species may be an unknown.

The FlowCAT system is capable of producing results from just a few millilitres of product, but retains the ability to ramp up production volumes once ideal conditions are identified.

At the heart of the system is a tubular reactor with a standard 3mL or 12mL isothermal reaction zone. The system operates up to 400°C and 200Bar. Any heterogeneous catalyst can be used and users can pack their own columns. The wide-bore reactor removes any propensity for blockages and further extends the reliability of the system, the company says.

See more

You may also like

Manufacturing

Lonza appoints Hans Trees as Global Head of Communications

Read more
Hans Trees will join Lonza as Global Head of Communications, Senior Vice President and Member of the Extended Executive Committee, effective 1 September 2026. Hans combines deep industry experience with a strong track record in stakeholder engagement, most recently serving as Global Head of External Engagement at Roche

Trending Articles

  1. Compact, economical and sustainable cooling solutions for laboratories Huber Unichillers offer space-saving and environmentally friendly temperature control for research and industrial applications
  2. Aragen to manufacture Renaissance Pharma’s FDA Fast Track mAb as part of ongoing strategic collaboration CRDMO successfully scaled and transferred Renaissance Pharma’s lead candidate, Daretabart a humanised monoclonal antibody targeting GD2 for high-risk neuroblastoma, in just 9 months
  3. Bruker announces major strides in 4D proteomics performance, further advances In intact and top-down functional proteoform analysis, and innovations in hybrid qual/quant 4D metabolomics All to enable deeper insights into disease biology. Bruker Also Launches Two Novel Mass Spectrometry Systems for Unique Applications in Energy Industry Research, and in Semiconductor Manufacturing
  4. CEPI fast-tracks three Bundibugyo ebolavirus vaccine candidates amid DRC outbreak With no licensed vaccines available and more than 900 suspected cases already recorded, CEPI is urgently advancing mRNA, rVSV and viral vector candidates from Moderna, IAVI and Oxford/SII toward clinical trials
  5. FDA Form 483 flags falsified records and live bird infestation at Dabur India OTC plant A FDA inspection report issued in January 2026 has revealed widespread CGMP failures at Dabur India's Dadra and Nagar Haveli facility, including manipulated microbiology data, fraudulent equipment logs and unsanitary storage conditions

Upcoming event

BIO International Convention

22–25 June 2026 | Convention | Boston, US See all

You may also like

Manufacturing

Lonza appoints Hans Trees as Global Head of Communications

Hans Trees will join Lonza as Global Head of Communications, Senior Vice President and Member of the Extended Executive Committee, effective 1 September 2026. Hans combines deep industry experience with a strong track record in stakeholder engagement, most recently serving as Global Head of External Engagement at Roche
Manufacturing

AlzeCure licenses Alzheimer’s candidate ACD680 to Lilly in deal worth up to $1bn

AlzeCure Pharma has entered a global licensing and collaboration agreement with Eli Lilly for its Alzheimer's disease candidate ACD680, securing a $10m upfront payment and potential milestone payments exceeding $1bn
Manufacturing

Safety in pharmaceutical manufacturing: why a trusted partner makes all the difference

By taking a three-tiered approach to protecting patients and personnel and ensuring plant compliance, GEA adopts a consultative approach to helping its customers navigate the responsibilities of pharmaceutical manufacturing safety with confidence
Manufacturing

Aragen to manufacture Renaissance Pharma’s FDA Fast Track mAb as part of ongoing strategic collaboration

CRDMO successfully scaled and transferred Renaissance Pharma’s lead candidate, Daretabart a humanised monoclonal antibody targeting GD2 for high-risk neuroblastoma, in just 9 months
Manufacturing

Cutting-edge wiped film evaporator installation – non-tobacco nicotine products

Successful system installation for a UK research and development facility developing and commercialising non-tobacco nicotine products using industry-leading evaporation equipment
Manufacturing

Next expansion milestone achieved: SCHOTT Pharma opens production facility in Serbia to strengthen competitiveness in Europe

After a double-digit million euro investment and less than 1.5 years of construction, SCHOTT Pharma opens new manufacturing site in Jagodina, Serbia. Production capacity to meet European market demand for pharmaceutical ampoules. Facility brings around 180 new jobs to the region
Manufacturing

Why integrated outsourcing wins in modern drug development

Aligning drug substance and drug product development within a single outsourcing model accelerates timelines, sharpens CMC decisions and reduces risk by enabling parallel workstreams and shared governance
Subscribe now